Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD) in a move that could help drive uptake of the latter's
Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal.
There is broad recognition of the need to promote diversity and inclusion in clinical trials, with the goal of improving health equity and enhancing the validity and generalisability of stu
Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors.
An FDA-approved digital therapeutic (DTx) that can be used to help people living with major depressive disorder (MDD) has been launched in the US and is available in mobile app stores.
